Advertisement
ADPT vs AXON
Which Stock Would AI Choose? Adaptive Biotechnologies (ADPT) vs. Axon Enterprise (AXON) Stock Comparison
Key Takeaways
- Adaptive Biotechnologies (ADPT) operates in the biotechnology sector with a focus on immune-driven medicine, while Axon Enterprise (AXON) delivers public safety technology solutions including conducted energy devices and digital evidence management.
- AXON has shown stronger recent momentum, with an approximate 24.6% rally over the 30 days ending in late July 2026, supported by consistent revenue growth exceeding 30% year-over-year in recent quarters.
- ADPT’s performance has been more subdued amid typical biotech sector dynamics, with limited specific catalysts reported in recent market activity compared to AXON’s visibility around its upcoming earnings release.
- AXON benefits from exposure to government and law enforcement spending, providing relative stability, whereas ADPT faces risks common to clinical-stage biotech firms such as regulatory outcomes and development timelines.
- Market sentiment favors AXON due to its growth trajectory and positioning ahead of second-quarter 2026 results scheduled for August 5, 2026, while ADPT sentiment remains tied to longer-term platform advancements.
- Both companies trade in distinct sectors—biotechnology versus public safety technology—creating trade-offs in growth drivers, volatility profiles, and sensitivity to macroeconomic factors.
Introduction
This comparison examines Adaptive Biotechnologies (ADPT) and Axon Enterprise (AXON) to highlight differences in business models, recent performance trends, and market positioning. The analysis draws on observable factors such as revenue trends, sector exposure, and relative price behavior over recent weeks. Institutional investors, growth-oriented traders, and sector specialists evaluating technology-driven companies in healthcare and public safety may find the relative performance and risk profiles relevant for portfolio construction or tactical allocation decisions.
ADPT Overview and Recent Performance
Adaptive Biotechnologies (ADPT) is a commercial-stage biotechnology company focused on translating the genetic language of the adaptive immune system into clinical products for disease diagnosis and treatment. Its core platform supports immunoSEQ for research applications and clonoSEQ, a next-generation sequencing assay for minimal residual disease detection in blood cancers. In recent market activity, ADPT has exhibited relatively contained price movements without standout catalysts, consistent with broader biotechnology sector dynamics influenced by clinical pipeline updates and funding environments. Sentiment remains anchored to long-term platform potential rather than short-term revenue inflection points.
AXON Overview and Recent Performance
Axon Enterprise (AXON) provides public safety technology solutions, operating in Software and Services and Connected Devices segments. Offerings include body-worn cameras, TASER conducted energy devices, cloud-based evidence management, and related hardware. Over recent weeks, AXON demonstrated notable strength, delivering an approximate 24.6% gain in the 30 days through late July 2026 amid sustained revenue expansion exceeding 30% year-over-year in the first quarter. The stock has traded above key moving averages following a period of volatility, with attention centered on the second-quarter 2026 earnings release planned for August 5, 2026.
Trending AI Robots
Tickeron maintains a curated Trending AI Robots section on its platform that features select AI trading bots optimized for prevailing market conditions. While the site hosts hundreds of AI trading bots capable of trading thousands of different tickers, only those demonstrating the strongest alignment with current trends, performance metrics, and risk-adjusted statistics earn placement in this highlighted area. Available bots span diverse trading styles, strategies, timeframes, and ticker sets, with performance ranges varying widely based on backtested and live results. This resource allows users to explore automated approaches tailored to individual preferences. For more details, visit the Trending AI Robots page.
Head-to-Head Comparison
Adaptive Biotechnologies (ADPT) and Axon Enterprise (AXON) operate in fundamentally different sectors, creating clear contrasts in growth drivers and risk exposures. ADPT’s biotechnology focus centers on immune medicine platforms with revenue tied to diagnostic assays and potential therapeutic applications, exposing it to clinical development timelines and regulatory milestones. In contrast, AXON generates recurring revenue through software subscriptions and hardware sales to government and law enforcement customers, benefiting from more predictable procurement cycles. Recent momentum has favored AXON, with its 24.6% 30-day advance contrasting ADPT’s more muted activity. Risk factors differ markedly: ADPT contends with typical biotech volatility around trial outcomes, while AXON faces execution risks around product adoption and competition in public safety technology. Market sentiment currently tilts toward AXON due to its growth consistency and earnings visibility, whereas ADPT sentiment hinges on longer-horizon platform validation.
Tickeron AI Verdict
Based on observable factors including recent trend consistency, revenue growth stability, and positioning ahead of near-term catalysts, Tickeron’s AI would currently assign a higher probabilistic preference to Axon Enterprise (AXON) over Adaptive Biotechnologies (ADPT). AXON’s documented rally and sector tailwinds provide measurable momentum signals relative to ADPT’s quieter recent period. This assessment reflects data-driven positioning rather than absolute outcomes and remains subject to evolving market conditions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADPT is a Buy and AXON is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ADPT’s FA Score shows that 0 FA rating(s) are green whileAXON’s FA Score has 0 green FA rating(s).
- ADPT’s FA Score: 0 green, 5 red.
- AXON’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ADPT’s TA Score shows that 4 TA indicator(s) are bullish while AXON’s TA Score has 4 bullish TA indicator(s).
- ADPT’s TA Score: 4 bullish, 4 bearish.
- AXON’s TA Score: 4 bullish, 4 bearish.
Price Growth
ADPT (@Medical Specialties) experienced а +10.13% price change this week, while AXON (@Aerospace & Defense) price change was +3.55% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +3.40%. For the same industry, the average monthly price growth was +7.31%, and the average quarterly price growth was +27.41%.
The average weekly price growth across all stocks in the @Aerospace & Defense industry was +2.20%. For the same industry, the average monthly price growth was +4.03%, and the average quarterly price growth was +6.47%.
Reported Earning Dates
ADPT is expected to report earnings on Nov 05, 2026.
AXON is expected to report earnings on Nov 10, 2026.
Industries' Descriptions
@Medical Specialties (+3.40% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Aerospace & Defense (+2.20% weekly)Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.
| ADPT | AXON | ADPT / AXON | |
| Capitalization | 4.05B | 48.4B | 8% |
| EBITDA | -20.94M | 320M | -7% |
| Gain YTD | 56.712 | 5.001 | 1,134% |
| P/E Ratio | N/A | 248.47 | - |
| Revenue | 295M | 2.98B | 10% |
| Total Cash | 218M | 737M | 30% |
| Total Debt | 77.6M | 1.83B | 4% |
ADPT | AXON | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 47 Fair valued | 90 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 58 | |
SMR RATING 1..100 | 98 | 82 | |
PRICE GROWTH RATING 1..100 | 35 | 45 | |
P/E GROWTH RATING 1..100 | 100 | 40 | |
SEASONALITY SCORE 1..100 | 35 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ADPT's Valuation (47) in the Hospital Or Nursing Management industry is somewhat better than the same rating for AXON (90) in the Biotechnology industry. This means that ADPT’s stock grew somewhat faster than AXON’s over the last 12 months.
AXON's Profit vs Risk Rating (58) in the Biotechnology industry is somewhat better than the same rating for ADPT (100) in the Hospital Or Nursing Management industry. This means that AXON’s stock grew somewhat faster than ADPT’s over the last 12 months.
AXON's SMR Rating (82) in the Biotechnology industry is in the same range as ADPT (98) in the Hospital Or Nursing Management industry. This means that AXON’s stock grew similarly to ADPT’s over the last 12 months.
ADPT's Price Growth Rating (35) in the Hospital Or Nursing Management industry is in the same range as AXON (45) in the Biotechnology industry. This means that ADPT’s stock grew similarly to AXON’s over the last 12 months.
AXON's P/E Growth Rating (40) in the Biotechnology industry is somewhat better than the same rating for ADPT (100) in the Hospital Or Nursing Management industry. This means that AXON’s stock grew somewhat faster than ADPT’s over the last 12 months.
| ADPT | AXON | |
|---|---|---|
| RSI ODDS (%) | 5 days ago 79% | 5 days ago 69% |
| Stochastic ODDS (%) | 5 days ago 80% | 5 days ago 78% |
| Momentum ODDS (%) | 5 days ago 90% | 5 days ago 76% |
| MACD ODDS (%) | 5 days ago 85% | 5 days ago 76% |
| TrendWeek ODDS (%) | 5 days ago 83% | 5 days ago 76% |
| TrendMonth ODDS (%) | 5 days ago 83% | 5 days ago 70% |
| Advances ODDS (%) | 7 days ago 83% | 7 days ago 74% |
| Declines ODDS (%) | 30 days ago 86% | 13 days ago 70% |
| BollingerBands ODDS (%) | 5 days ago 84% | 5 days ago 65% |
| Aroon ODDS (%) | 5 days ago 86% | 7 days ago 80% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| PCGG | 11.57 | 0.07 | +0.61% |
| Polen Capital Global Growth ETF | |||
| CSTK | 33.88 | 0.12 | +0.37% |
| Invesco Comstock Contrarian Equity ETF | |||
| DIVO | 48.16 | 0.16 | +0.33% |
| Amplify CWP Enhanced Dividend Income ETF | |||
| SJB | 15.17 | 0.02 | +0.17% |
| ProShares Short High Yield | |||
| FIIG | 20.40 | -0.08 | -0.41% |
| First Trust Intermediate DurInvGrdCrpETF | |||
ADPT and
Correlation & Price change
A.I.dvisor indicates that over the last year, ADPT has been loosely correlated with AXON. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if ADPT jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To ADPT | 1D Price Change % | ||
|---|---|---|---|---|
| ADPT | 100% | +2.09% | ||
| AXON - ADPT | 56% Loosely correlated | +4.43% | ||
| VCYT - ADPT | 53% Loosely correlated | -2.01% | ||
| PSNL - ADPT | 51% Loosely correlated | +2.40% | ||
| ARRY - ADPT | 50% Loosely correlated | -4.14% | ||
| NTRA - ADPT | 49% Loosely correlated | -1.16% | ||
More | ||||